Melissa Engle

1.8k total citations
19 papers, 786 citations indexed

About

Melissa Engle is a scholar working on Infectious Diseases, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Melissa Engle has authored 19 papers receiving a total of 786 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 11 papers in Epidemiology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Melissa Engle's work include Tuberculosis Research and Epidemiology (12 papers), Pneumonia and Respiratory Infections (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Melissa Engle is often cited by papers focused on Tuberculosis Research and Epidemiology (12 papers), Pneumonia and Respiratory Infections (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Melissa Engle collaborates with scholars based in United States, Uganda and South Africa. Melissa Engle's co-authors include Marc Weiner, Andrew Vernon, William J. Burman, Charles A. Peloquin, John L. Johnson, Stefan Goldberg, Zhen Zhao, William R. Mac Kenzie, Thomas J. Prihoda and Grace Muzanye and has published in prestigious journals such as JAMA, American Journal of Respiratory and Critical Care Medicine and Clinical Infectious Diseases.

In The Last Decade

Melissa Engle

17 papers receiving 758 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melissa Engle United States	13	584	408	163	132	113	19	786
Hanneke M. J. Nijland Netherlands	6	505 0.9×	368 0.9×	173 1.1×	149 1.1×	63 0.6×	7	660
Emmanuel Chigutsa United States	15	526 0.9×	237 0.6×	119 0.7×	180 1.4×	94 0.8×	28	857
Rosa María López Spain	18	534 0.9×	326 0.8×	126 0.8×	86 0.7×	103 0.9×	44	888
Chantal Valiquette Canada	7	462 0.8×	327 0.8×	165 1.0×	78 0.6×	61 0.5×	12	742
Amina Jindani United Kingdom	15	970 1.7×	893 2.2×	437 2.7×	126 1.0×	200 1.8×	23	1.4k
Erin Bliven-Sizemore United States	10	910 1.6×	661 1.6×	420 2.6×	75 0.6×	96 0.8×	14	1.0k
Leonor Pou Spain	17	454 0.8×	293 0.7×	192 1.2×	63 0.5×	58 0.5×	29	900
Shenjie Tang China	15	768 1.3×	552 1.4×	284 1.7×	47 0.4×	174 1.5×	64	960
Eric Nuermberger United States	19	1.2k 2.0×	831 2.0×	401 2.5×	198 1.5×	308 2.7×	21	1.4k
Pauline Howell South Africa	8	606 1.0×	383 0.9×	564 3.5×	66 0.5×	200 1.8×	20	1.2k

Countries citing papers authored by Melissa Engle

Since Specialization

Citations

This map shows the geographic impact of Melissa Engle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Engle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Engle more than expected).

Fields of papers citing papers by Melissa Engle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Engle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Engle. The network helps show where Melissa Engle may publish in the future.

Co-authorship network of co-authors of Melissa Engle

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Engle. A scholar is included among the top collaborators of Melissa Engle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Engle. Melissa Engle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kurbatova, Ekaterina V., William C. Whitworth, Patrick Phillips, et al.. (2025). Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerging infectious diseases. 31(3). 467–476.

Mangan, Joan M., Mike Frick, Lindsay McKenna, et al.. (2024). Facilitators and barriers to adolescent participation in a TB clinical trial. The International Journal of Tuberculosis and Lung Disease. 28(5). 243–248.

Weiner, Marc, Jon Gelfond, Teresa L. Johnson‐Pais, et al.. (2020). Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. Journal of Antimicrobial Chemotherapy. 76(3). 582–586. 13 indexed citations

Weiner, Marc, Jon Gelfond, Teresa L. Johnson‐Pais, et al.. (2018). Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.−11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy. 62(5). 15 indexed citations

Weiner, Marc, et al.. (2017). Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials. Clinical Pharmacology & Therapeutics. 102(2). 321–331. 54 indexed citations

Jayakumar, Angelina, Eric Vittinghoff, Mark R. Segal, et al.. (2015). Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis. 95(4). 415–420. 30 indexed citations

Nahid, Payam, Erin Bliven-Sizemore, Leah G. Jarlsberg, et al.. (2014). Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis. 94(3). 187–196. 50 indexed citations

Weiner, Marc, Radojka M. Savić, William R. Mac Kenzie, et al.. (2014). Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. Journal of the Pediatric Infectious Diseases Society. 3(2). 132–145. 35 indexed citations

Weiner, Marc, Eric F. Egelund, Melissa Engle, et al.. (2013). Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. Journal of Antimicrobial Chemotherapy. 69(4). 1079–1085. 42 indexed citations

10.

Nsubuga, Peter, Grace Muzanyi, Micheal Mugerwa, et al.. (2012). Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment. The International Journal of Tuberculosis and Lung Disease. 16(4). 480–485. 6 indexed citations

11.

Weiner, Marc, Charles A. Peloquin, Eric F. Egelund, et al.. (2011). Rifapentine Exposure In A Trial Of Daily Rifapentine Compared To Rifampin During The Intensive Phase Of TB Treatment. A6341–A6341. 2 indexed citations

12.

Weiner, Marc, Charles A. Peloquin, William J. Burman, et al.. (2010). Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations. Antimicrobial Agents and Chemotherapy. 54(10). 4192–4200. 114 indexed citations

13.

Weiner, Marc, Thomas J. Prihoda, William J. Burman, et al.. (2010). Evaluation of Time to Detection of Mycobacterium tuberculosis in Broth Culture as a Determinant for End Points in Treatment Trials. Journal of Clinical Microbiology. 48(12). 4370–4376. 12 indexed citations

14.

Benator, Debra, Marc Weiner, William J. Burman, et al.. (2007). Clinical Evaluation of the Nelfinavir‐Rifabutin Interaction in Patients with Tuberculosis and Human Immunodeficiency Virus Infection. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(6). 793–800. 10 indexed citations

15.

Weiner, Marc, William J. Burman, Charles A. Peloquin, et al.. (2007). Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin. Antimicrobial Agents and Chemotherapy. 51(8). 2861–2866. 84 indexed citations

16.

Burman, William J., Stefan Goldberg, John L. Johnson, et al.. (2006). Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 174(3). 331–338. 207 indexed citations

17.

Benator, Debra, Charles A. Peloquin, W. J. Burman, et al.. (2005). Evaluation of the Drug Interaction between Rifabutin and Efavirenz in Patients with HIV Infection and Tuberculosis. Clinical Infectious Diseases. 41(9). 1343–1349. 43 indexed citations

18.

Anzueto, Antonio, Amal Jubran, Jill Ohar, et al.. (1998). Effects of Aerosolized Surfactant in Patients with Stable Chronic Bronchitis. Survey of Anesthesiology. 42(5). 304–304. 5 indexed citations

19.

Anzueto, Antonio, Amal Jubran, Jill Ohar, et al.. (1997). Effects of Aerosolized Surfactant in Patients With Stable Chronic Bronchitis. JAMA. 278(17). 1426–1426. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact